Latest analyses
| Document | Brief | Topic | Published |
|---|---|---|---|
| PRX-BRF-004 | Don't wait for the FDA milestone to start on market accessCoding, coverage, and payment run on calendars that start before clearance and close on their own schedule. What to do before submission, during review, and at clearance.Read the analysis | Strategy | September 2026 |
| PRX-BRF-003 | How to evaluate synthetic payer research before you trust itSimulated payer panels went from novelty to product category in one year. A buyer's checklist for separating validated simulation from expensive improv.Read the analysis | Method | August 2026 |
| PRX-BRF-002 | Your market access landscape was stale the day it arrivedPolicies, fee schedules, and code statuses move on a quarterly rhythm. The industry's snapshot deliverable model cannot keep up, and there is now a better architecture.Read the analysis | Method | July 2026 |
| PRX-BRF-001 | RAPID replaced TCET. Most device companies have not caught upCMS paused the TCET pathway in April and pointed Breakthrough-designated devices at RAPID. The window rewards companies that move while competitors are still citing the old rule.Read the analysis | Policy | July 2026 |
Have a question these should answer?
Tell us what you are wrestling with. It might become the next analysis, and either way you will get our current read.